A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal ...
The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...
Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, ...
Number 3: The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and ...
Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in ...
Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...
Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...
The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...
On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and ...
Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...
In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...
Steve Pickette, PharmD, BCPS, chief clinical pharmacist at InpharmD, highlighted the transformative role of artificial intelligence (AI) in managing biosimilars and generics. He explains that AI can ...